Answers are grounded in this paper and cite their sources.
The A-domain of IGF-I is primarily responsible for its growth-promoting ability, whereas the B-domain mediates recognition by IGF carrier proteins.
A two-chain, disulfide linked, insulin-like compound embodying the A-domain of insulin-like growth factor I (IGF-I) and the B-chain of insulin has been synthesized and characterized with respect to insulin-like biological activity and growth-promoting potency. The compound displays a potency of ca. 41% relative to insulin in assays for insulin-like activity (e.g., lipogenesis) but significantly higher activity than insulin, ca. 730% relative to insulin, in growth factor assays (e.g., thymidine incorporation). The compound is, however, a less potent growth factor than IGF-I itself, ca. 26.5% relative to IGF-I, and is not recognized by IGF carrier proteins. We conclude that structural features contained in the A-domain of IGF-I are primarily responsible for the growth-promoting ability displayed by IGF-I, while features in the B-domain are responsible for recognition by IGF carrier proteins.
No takes yet. Share an insight, caveat, or question.
Chen et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: